Tocofersolan
Names | |
---|---|
IUPAC name
α-[4-[[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy]-1,4-dioxobutyl]-ω-hydroxy-poly(oxy-1,2-ethanediyl)
| |
Other names
Tocofersolan; Vitamin E PEG succinate; α-Tocopherol polyethylene glycol succinate; Liqui-E
| |
Identifiers | |
3D model (JSmol)
|
|
ChemSpider | |
ECHA InfoCard | Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). |
PubChem CID
|
|
UNII | |
| |
| |
Properties | |
(C2H4O)nC33H54O5 | |
Molar mass | Variable |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
verify (what is ?) | |
Infobox references | |
WikiDoc Resources for Tocofersolan |
Articles |
---|
Most recent articles on Tocofersolan Most cited articles on Tocofersolan |
Media |
Powerpoint slides on Tocofersolan |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Tocofersolan at Clinical Trials.gov Clinical Trials on Tocofersolan at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Tocofersolan
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Tocofersolan Discussion groups on Tocofersolan Patient Handouts on Tocofersolan Directions to Hospitals Treating Tocofersolan Risk calculators and risk factors for Tocofersolan
|
Healthcare Provider Resources |
Causes & Risk Factors for Tocofersolan |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Tocofersolan (INN) or tocophersolan is a synthetic water-soluble version of vitamin E. Natural forms of vitamin E are fat soluble, but not water-soluble. Tocofersolan is polyethylene glycol derivative of α-tocopherol that enables water solubility.
Tocofersolan is used as a vitamin E supplement or to treat vitamin E deficiency in individuals who cannot absorb fats due to disease.[1] On 24 July 2009 the European Medicines Agency approved tocofersolan under the trade name Vedrop 50 mg/ml oral solution for the treatment of vitamin E deficiency due to digestive malabsorption in paediatric patients suffering from congenital or hereditary chronic cholestasis, from birth (in term newborns) to 16 or 18 years of age (depending on the region).[2]
Tocofersolan is also used in cosmetics and pharmaceuticals as an antioxidant.[3]
References
- ↑ "Tocophersolan Oral". WebMD.
- ↑ "Vedrop Summary of Product Characteristics" (PDF). European Medicines Agency.
- ↑ Ash, Michael; Ash, Irene. Handbook of Preservatives. p. 568. ISBN 1-890595-66-7.